Aspen is evaluating ANPD001 in the Trial-Ready Cohort Study launched last month as a preliminary step to filing an Investigational New Drug (IND) application with the FDA. Through the screening study, the company is taking biopsies from 20–30 patients, from which Aspen plans to identify the 10–20 patients who will be assessed further in the Phase I/IIa trial it plans to launch over the coming year . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge